In a rapid response to increasing regulatory scrutiny and legal threats from pharmaceutical giant Novo Nordisk, Hims & Hers has decided to withdraw its recently launched knockoff weight-loss pill based on the semaglutide formula used in Wegovy. The FDA has warned of impending actions against illegal copycat drugs, further prompting the company to halt the sale of its compounded version of the obesity medication. As a result of these developments, the stock of Hims & Hers has seen a significant decline. Amidst the scrutiny, Hims & Hers also announced plans to offer a cheaper alternative to Wegovy, raising concerns over the legality of such compounding practices and their impact on innovation within the pharmaceutical industry.